secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-211860
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS
----------------------------------------------------------------------

- Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.
- TAVNEOS (avacopan) is a first-in-class oral C5aR inhibitor approved Oct 2021 for ANCA-associated vasculitis; Q1 2022 US sales $5.4M.
- Transaction expected to close Q4 2022, subject to ChemoCentryx stockholder approval, HSR clearance, and other conditions.
- ChemoCentryx must pay Amgen a termination fee of ~$119M if it terminates for a superior proposal or under certain circumstances.
- Acquisition includes early-stage pipeline: three inflammatory disease candidates and an oral checkpoint inhibitor for cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/0001193125-22-211860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312522211860/d346334d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-211860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer